Soligenix, Inc. announced the appointment of Marco Maria Brughera, DVM, Global Head of the Rare Disease Franchise for Sigma-Tau SpA, to its Board of Directors. Since January 2011, Dr. Brughera has held several positions for the Sigma-Tau Group, including Corporate Research and Development Managing Director of Sigma-Tau SpA, President of Sigma-Tau Research and Board Member of Sigma-Tau Pharmaceuticals. He currently serves on the Board of Gentium SpA.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.315 USD | -10.00% | -13.70% | -58.40% |
May. 23 | Sector Update: Health Care Stocks Retreat Late Afternoon | MT |
May. 23 | Sector Update: Health Care Stocks Lower Thursday Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-58.40% | 4.49M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- SNGX Stock
- News Soligenix, Inc.
- Soligenix, Inc. Appoints Marco Maria Brughera to the Board of Directors